BTAI News and Press, BioXcel Therapeutics Inc.

2024-07-16 07:23:06 ET More on BioXcel Therapeutics BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on BioXcel Therapeutics Historical earnings data for BioXcel Therapeutics Financial information for BioX...

Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...

Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...

NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...

NEW HAVEN, Conn., May 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that Rob Risinger, M.D., Chief Medical Officer ...

2024-05-09 11:58:09 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioXcel Therapeutics (NASDAQ: BTAI ) just reported results for the first quarter of 2024. BioXcel Therapeutics reported earnings per share of -87 cents. This was below the...

2024-05-09 09:53:09 ET BioXcel Therapeutics, Inc. (BTAI) Q1 2024 Results Earnings Conference Call May 9, 2024, 08:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer and Founder Vincent O'Neill - Executive Vice President and Chief of Product Developme...

2024-05-09 07:07:42 ET More on BioXcel Therapeutics BioXcel Therapeutics, Inc. (BTAI) Q4 2023 Earnings Call Transcript BioXcel launches $25M direct offering of stock and warrants UBS cuts BioXcel to neutral; cites regulatory issues, financing Seeking Alpha&#x...

AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...

Advancing TRANQUILITY and SERENITY program plans for two pivotal Phase 3 trials to expand BXCL501 market potential in acute treatment of agitation Strengthened intellectual property portfolio for BXCL501 with grant of two new patents, in Japan and the U.S. Completed $25 million re...